Abstract: The invention relates, in part, to compounds, compositions, and methods comprising Thiostreopton (TS) that are useful to treat cancer in cells and subjects.

Abstract: A formation of multielement nanoparticles is disclosed that includes at least three elements. Each of the at least three elements is uniformly distributed within the multielement nanoparticles forming nanoparticles having a homogeneous mixing structure. At least five elements may form a high-entropy nanoparticle structure. A method for manufacturing a formation of multielement nanoparticles includes providing a precursor material composed of the at least three component elements in multielement nanoparticles; heating the precursor material to a temperature and a time; and quenching the precursor to a temperature at a cooling rate to result in a formation of multielement nanoparticles containing at least three elements and the heating and the quenching representing a multielement nanoparticle thermal shock formation process. A corresponding system for manufacturing the formation of multielement nanoparticles and a method of using the multielement nanoparticles are also disclosed.

Abstract: Provided are lincosamide compounds for the treatment of infectious diseases. The lincosaniides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamycin. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.

Abstract: Described herein are methods and compositions related to a method of treating a neurodevelopmental disorder in a subject in need thereof, the method comprises administering to the subject an agent that increases the level or activity of interleukin-17a (IL-17a) in the brain. The method can further comprise administering an agent that increases the permeability of the blood brain barrier.

Abstract: A nanobiocatalytic membrane for a filtration system is provided which includes a filtration membrane and a plurality of nanobiocatalyst nanoparticles associated with the membrane, each of the nanobiocatalyst nanoparticles including a core, a coating at least partially surrounding the core, and a plurality of nanobiocatalysts coupled to the coating. Each of the plurality of nanobiocatalysts includes an antibacterial nanoparticle comprising bismuth, and a quorum quenching agent coupled to the antibacterial nanoparticle. A nanobiocatalyst nanoparticle for use with a water purification system is also provided. A method of forming a nanobiocatalytic membrane for a filtration system and a method of using a nanobiocatalytic membrane in a filtration system are also provided.

Abstract: The invention relates, in part, to compounds, compositions, and methods to reduce infectivity of virus particles and to treat viral infections in subjects.

Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cpf1 or variants thereof, and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a napDNAbp (e.g., CasX, CasY, Cpf1, C2c1, C2c2, C2C3, and Argonaute) and nucleic acid editing proteins or domains, are provided.

Abstract: Disclosed is a test tube rack designed to hold a plurality of test tubes suspended in a bath. The rack is a unitary design having an outer rim with an internal diameter sized to fit over a rim of a vessel that forms the bath. The rack includes a plurality of openings sized to fit a test tube. A top end of each opening includes a plurality of raised portions and a plurality of lowered portions. The raised portions support an outwardly flared rim of a test tube placed in the opening and thus suspends the test tube in the vessel. A central hub joins the plurality of openings together. The rack is formed from a temperature resistant material and can be utilized with both cold and hot baths. The rack is economical and readily scalable to work in conjunction with a variety of vessel sizes.

Abstract: Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.

Abstract: Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.

Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.

Abstract: An electro-acupuncture (EA) system and method for performing EA on a patient are provided. The EA system comprises a wearable neurostimulator device, at least a first pair of electrically-conductive acupuncture needles and a system controller. The wearable neurostimulator device comprises a casing, an EA circuit mechanically coupled to the casing, and an attachment device mechanically coupled to the casing and adapted to removably secure the wearable neurostimulator device to the patient. The first pair of electrically-conductive acupuncture needles is mechanically coupled to the casing and electrically coupled to the EA circuit. The system controller is in communication with the EA circuit of the wearable neurostimulator device via a communication link and controls the EA circuit to cause the EA circuit to output an output voltage selected by the system controller at a frequency selected by the system controller.

Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.

Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.

Abstract: A 3-D printed device comprising one or more interconnect structures, the interconnect structures comprising a plurality of conductive particles and one or more diblock or triblock copolymers; the diblock or triblock copolymers having an A-B, A-B-A, or A-B-C block-type structure in which the A-blocks and C-blocks are an aromatic-based polymer or an acrylate-based polymer and the B-blocks are an aliphatic-based polymer. These 3-D printed devices may be formed using a method that comprises providing a conductive ink composition; applying the conductive ink composition to a substrate in a 3-D solvent cast printing process to form one or more interconnect structures; and drying the one or more interconnect structures formed from the conductive ink composition. The dried interconnect structures exhibit a conductivity equal to or greater than 1×105 S/m without having to be subjected to any post-processing sintering treatment.

Abstract: Provided herein relates to implantable devices and systems with dynamic silk coatings. In some embodiments, the dynamic silk coatings can be formed in situ or in vivo.

Abstract: Engineered Cementitious Composites (ECC) and cement products including Engineered Cementitious Composites are provided. The ECC can include cement, sugar cane bagasse ash, and fiber. The sugar cane bagasse ash can be processed to provide a partial cement or sand replacement in ECCs and cement products.

Abstract: The present disclosure provides, in some embodiments, methods and compositions for single-molecule detection.

Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.

Abstract: The present invention generally relates to systems and methods for imaging or determining nucleic acids in cells or other samples. In some cases, the transcriptome of a cell may be determined. Certain embodiments are generally directed to determining nucleic acids and other targets in a sample at relatively high resolutions. For instance, nucleic acid probes may be applied to sample, and binding of the nucleic acid probes to a target may be amplified using primary and secondary amplifier nucleic acids. In some cases, there is a maximum number of amplifier nucleic acids that can be bound to a target, e.g., the binding is saturatable, and cannot grow indefinitely, even in the presence of abundant reagents. This may be advantageous, for example, for controlling the brightness of each binding event, controlling the size of the amplified regions (e.g., during imaging), and/or for limiting the degree of amplification noise (i.e. the final variation in amplified signal from molecule to molecule), etc.